Skip to main content
Announcements

Sidley Represents Dechra in Acquisition of Gallant Pet

November 18, 2026

Sidley represented Dechra, a global leader in veterinary specialty care, in its acquisition of Gallant Pet Inc., a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets. The acquisition expands Dechra’s portfolio into regenerative medicine, adding an innovative therapeutic platform with the potential to address unmet medical needs and broaden treatment options for chronic and complex conditions in companion animals.

The Sidley team was led by Chris Boyle (Food, Drug and Medical Device), Rosemary Reilly (Emerging Companies and Venture Capital), and Emily Hunter (Private Equity); and included Elina Sigal (Private Equity); Adriana Tibbitts, Karena Kong, and Patrick Donaldson (Technology and Life Sciences Transactions); Sarah Wiley and Adrianna Ramirez Mateo (M&A); Emily Marden and Kevin Sforza (Food, Drug and Medical Device); Eric Wolf and Ryan McLeod (Employee Benefits and Executive Compensation); Christian Brause and Daniel Venetucci (Tax); Amy Mahan (IP Litigation); Ryan Mulligan (White Collar Defense and Investigations); Stephen McInerney (Privacy and Cybersecurity); and Eric Kauffman (Labor, Employment and Immigration).